Esperion Therapeutics Inc... (ESPR)
NASDAQ: ESPR
· Real-Time Price · USD
0.80
-0.09 (-10.39%)
At close: May 09, 2025, 3:59 PM
0.80
0.24%
After-hours: May 09, 2025, 05:43 PM EDT
Esperion Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|
| Collaboration Revenue Revenue | 216.59M | 38M | 19.61M | 38.4M | 214.58M |
| Collaboration Revenue Revenue Growth | +469.99% | +93.75% | -48.93% | -82.10% | n/a |
| Product Revenue | 115.72M | 78.33M | 55.86M | 40.05M | n/a |
| Product Revenue Growth | +47.73% | +40.23% | +39.49% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 36.92M | 39.98M | 44.17M | 41.99M | 45.42M | 33.24M | 33.96M | 29.9M | 24.14M | 24.95M | 29.61M | 30.38M | 38.34M | 39.27M | 46.32M | 61.06M | 61.55M | 48.83M | 47.68M | 41.55M | 21.71M | 18.47M | 13.49M | 12.18M | 11.18M | 9.01M | 6.96M | 5.95M | 5.26M | 5.68M | 5.41M | 5.03M | 4.4M | 4.21M | 4.63M | 5.03M | 5.28M | 5.67M | 5.25M | 4.04M |
| Selling, General, and Administrative Revenue Growth | -7.63% | -9.51% | +5.21% | -7.55% | +36.63% | -2.12% | +13.57% | +23.88% | -3.27% | -15.72% | -2.54% | -20.75% | -2.36% | -15.23% | -24.15% | -0.80% | +26.07% | +2.40% | +14.75% | +91.38% | +17.57% | +36.88% | +10.75% | +9.00% | +24.03% | +29.54% | +16.83% | +13.26% | -7.46% | +4.97% | +7.62% | +14.19% | +4.51% | -9.04% | -7.91% | -4.68% | -6.95% | +7.98% | +30.19% | n/a |
| Research and Development Revenue | 10.98M | 10.4M | 11.46M | 13.4M | 17.74M | 14.88M | 22.1M | 31.38M | 33.03M | 29.14M | 32.43M | 24.32M | 27.62M | 25.33M | 25.07M | 27.95M | 41.96M | 35.28M | 34.99M | 34.7M | 38.23M | 48.28M | 42.79M | 46.31M | 49.47M | 41.55M | 39.52M | 40.94M | 33.44M | 40.06M | 38.25M | 35.86M | 24.88M | 13.5M | 9.7M | 9.79M | 7.96M | 7.25M | 7.21M | 7.39M |
| Research and Development Revenue Growth | +5.58% | -9.28% | -14.49% | -24.46% | +19.19% | -32.64% | -29.58% | -5.00% | +13.35% | -10.14% | +33.36% | -11.94% | +9.02% | +1.02% | -10.30% | -33.39% | +18.94% | +0.85% | +0.82% | -9.24% | -20.81% | +12.84% | -7.60% | -6.40% | +19.07% | +5.13% | -3.46% | +22.43% | -16.52% | +4.73% | +6.66% | +44.13% | +84.33% | +39.18% | -0.95% | +23.06% | +9.78% | +0.53% | -2.45% | n/a |